Compare IQIYI Inc - ADR (IQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs BIO-TECHNE Corp — how do they compare? IQIYI Inc - ADR trades at $1.23 (market cap $1.20B), while BIO-TECHNE Corp trades at $71.57 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 9.3× IQIYI Inc - ADR's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| IQ | TECH | |
|---|---|---|
Market Cap | $1.20B | $11.16B |
Sector | Media | Health |
52-Week High | $2.79 | $72.12 |
52-Week Low | $0.96 | $43.31 |
Enterprise Value | $2.76B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ stock trades at $1.235, up 3.78% today, with a bullish technical signal and mixed fundamentals. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, but valuation ratios like P/S of 0.3 and P/B of 0.6 appear low. Recent news highlights AI initiatives and leadership changes, while analyst consensus is split with 50% buy ratings.
The outlook is cautious due to profitability challenges and projected revenue decline in 2026, but low valuations and AI-driven content strategy offer potential upside. Key risks include competitive pressures in streaming and regulatory uncertainty in China.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
